Long Noncoding RNA FOXD2-AS1 Promotes Pancreas Adenocarcinoma Cell Invasion and Migration by Sponging miR-30a-3p to Upregulate COX-2

Ye, Zhihua; Yang, Yingyu; Wei, Ying; Li, Lamei; Wang, Xinyi; Zhang, Junkai

doi:10.1615/critreveukaryotgeneexpr.2021039235

Cited by 7 publications

(3 citation statements)

References 14 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple reports have shown that FOXD2-AS1 plays an important role in the development of multiple tumors, including the promotion of malignant progression of bile duct cancer via regulation of the miR-760/E2F3 axis ( Hu et al, 2022 ). FOXD2-AS1 may promote pancreatic cancer cell invasion and migration by sponging miR-30a-3p, which upregulates COX-2 ( Ye et al, 2022 ). FOXD2-AS1 promotes breast cancer cell proliferation, invasion, migration, and drug resistance by positively regulating the PI3K/AKT signaling pathway, inhibits apoptosis, and accelerates breast cancer progression ( Nong et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma

Huili

Nie²,

Zhang³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, accounting for approximately 70% of all RCC cases. Cuproptosis, a novel mechanism of cell death, may be a potential target for intervention in tumor development.Methods: Cuproptosis-related prognostic lncRNAs were identified by co-expression analysis and univariable Cox regression. Five lncRNA profiles were obtained by LASSO regression analysis, and a model with high accuracy was constructed to assess the prognosis of ccRCC patients based on these cuproptosis-related lncRNAs. Survival analysis and time-dependent ROC curves were performed for the α and β groups, and the results confirmed the high accuracy of the model in predicting the prognosis of ccRCC patients. Immunoassay, principal component analysis (PCA), and drug sensitivity analysis were also performed for different risk categories. Finally, we classified ccRCC patients into two different subtypes by consistent class clustering, and performed immune checkpoint activation, tumor microenvironment analysis, PCA, and drug sensitivity analysis for different subtypes.Results: We developed a prognostic model using five cuproptosis-associated lncRNAs, which was found to be highly accurate in predicting ccRCC patients’ prognosis. Immunotherapy may be more beneficial to the hyper-risk category and the C2 subtype.Conclusion: The results of this study confirm that five cuproptosis-associated lncRNAs can be used as potential prognostic markers for ccRCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma

Huili

Nie²,

Zhang³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…A total number of 179 tumors along with 171 normal tissues were included in the analysis. The association of ASF1B expression level with the overall survival of PDAC patients was analyzed using Kaplan–Meier Plotter in GEPIA online resources, with a total of 178 cases being included (Ye et al 2022 ). Four databases including Starbase ( https://starbase.sysu.edu.cn/starbase2/index.php ), Targetscan ( http://www.targetscan.org/vert_71/ ), miRDB ( http://mirdb.org/ ) and miRWalk ( http://mirwalk.umm.uni-heidelberg.de/ ) were employed to predict the miRNAs with possible binding sites with ASF1B mRNA.…”

Section: Methodsmentioning

confidence: 99%

miR-24-3p Regulates Epithelial–Mesenchymal Transition and the Malignant Phenotype of Pancreatic Adenocarcinoma by Regulating ASF1B Expression

et al. 2022

View full text Add to dashboard Cite

Anti-silencing function protein 1 homolog B (ASF1B) has been implicated in the occurrence and development of cancers. The present work explored the functional role and the expression regulation of ASF1B in pancreatic ductal adenocarcinoma (PDAC). Based on the real-time quantitative PCR (qRT-PCR) and immunohistochemistry (IHC), ASF1B was significantly upregulated in PDAC tissues. High expression of ASF1B was associated with a poor overall survival (OS) and recurrence-free survival (DFS) in the PDAC patients. ASF1B also showed a relatively higher expression in PDAC cells (AsPC-1, PANC-1) when compared with human pancreatic ductal epithelial cells (HPDFe-6). CCK8 and clone formation assay demonstrated that silencing ASF1B impaired the proliferation in PANC-1 and AsPC-1 cells, and Annexin V-PI staining showed an increased level of apoptosis upon ASF1B silencing. ASF1B silencing also suppressed the migration and invasion in PDAC cells, as revealed by Transwell assays. We further showed that miR-24-3p was downregulated in PDAC tissues and cells, which functionally interacted with ASF1B by dual-luciferase reporter assay. miR-24-3p negatively regulated ASF1B expression to modulate the malignant phenotype of PDAC cells. ASF1B shows high expression in PDAC, which promotes the malignancy and EMT process of PDAC cells. miR-24-3p is a negative regulator of ASF1B and is downregulated in PDAC cells. Our data suggest that targeting ASF1B/miR-24-3p axis may serve as an intervention strategy for the management of PDAC.

show abstract

“…Actually, the transcription of the entire eukaryotic genome will produce countless non-protein RNA species, and non-coding RNA (ncRNAs) is one of non-protein RNA species. 1 Studies showed that 80% of the DNA is transcribed into RNA but only a meager 1.5% of that RNA actually translates into protein. 2 Initially, ncRNAs were once considered as "evolutionary junk" lacking the potential to code protein.…”

Section: Introductionmentioning

confidence: 99%

The Function and Mechanism of Long Non-Coding RNA RP11-23J9.4 in Thyroid Cancer

Zhao

Zhong

Ding

et al. 2023

Crit Rev Eukaryot Gene Expr

View full text Add to dashboard Cite

Introduction: The objective of this research is to explore whether LncRNA RP11 23J9.4 can be used as a targeted marker for the treatment of thyroid cancer (TC), downregulation of LncRNA RP11 23J9.4 and X-ray radiation have synergistic inhibitory effect on TC. Methods: The expression of LncRNA RP11 23J9.4 in papillary thyroid carcinoma (PTC) cell was downregulated by cell transfection, and its inhibitory effect on PTC cells was proved through proliferation, invasion experiment, apoptosis, and cell cycle analysis. The transfected cells were irradiated with 2 Gy X-ray. The above methods were also used to detect whether they had synergistic inhibitory effect on TC. The expression of Axin2 gene and protein were detected by real-time PCR, Western blotting, and immunohistochemistry. Results: On the one hand, it is proved that downregulating the expression of LncRNA RP11 23J9.4 can inhibit the development of TC through Axin2. On the other hand, it is clear that downregulation of LncRNA RP11 23J9.4 and X-ray radiation have synergistic inhibitory effect on TC. Conclusions: LncRNA RP11 23J9.4 and X-ray have significant synergistic effect on TC. LncRNA RP11 23J9.4 can be used as a marker for TC targeted therapy.

show abstract

Long Noncoding RNA FOXD2-AS1 Promotes Pancreas Adenocarcinoma Cell Invasion and Migration by Sponging miR-30a-3p to Upregulate COX-2

Cited by 7 publications

References 14 publications

Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma

Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma

miR-24-3p Regulates Epithelial–Mesenchymal Transition and the Malignant Phenotype of Pancreatic Adenocarcinoma by Regulating ASF1B Expression

The Function and Mechanism of Long Non-Coding RNA RP11-23J9.4 in Thyroid Cancer

Contact Info

Product

Resources

About